Details of the Drug

General Information of Drug (ID: DMISH0Z)

Drug Name
Mogamulizumab
Indication
Disease Entry ICD 11 Status REF
Mycosis fungoides 2B01 Approved [1]
Sezary syndrome 2B02 Approved [1]
Cutaneous T-cell lymphoma 2B01 Phase 3 [2]
T-cell leukaemia 2A90 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
ATC Code
L01FX09: Mogamulizumab
L01FX: Other monoclonal antibodies and antibody drug conjugates
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 5577 mgh/L []
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 32 mg/L []
Clearance
The clearance of drug is 12 mL/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 17 days []
Vd
The volume of distribution (Vd) of drug is 3.6 L []
Cross-matching ID
UNII
YI437801BE
DrugBank ID
DB12498
TTD ID
D0W2HD
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 4 (CCR4) TT7HQD0 CCR4_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Mycosis fungoides
ICD Disease Classification 2B01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 4 (CCR4) DTT CCR4 2.33E-02 3.98E-03 0.03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mogamulizumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Mogamulizumab and Ozanimod. Multiple sclerosis [8A40] [4]

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
4 Cerner Multum, Inc. "UK Summary of Product Characteristics.".